BioXmark® _ The liquid fiducial marker
Enabling high precision in
- Image Guided RadioTherapy (IGRT)
- Proton Therapy
Link to: BioXmark Brochure
BioXmark® is under development and not yet CE marked.
The properties of BioXmark® have been verified in both animal models and in clinical trials.
BioXmark® has the potential to improve radiotherapy precision and therapy outcome.
It is provided as a sterile, transparent solution in ampoules containing 1mL each. It has a low initial viscosity. Once injected into soft tissue, a highly viscous fiducial marker is formed.
BioXmark® has a range of appealing properties compared to metal based markers currently used in the clinic:
- Visible on X-ray (kV, CT, CBCT, Flouroscopy), MRI and US
- Low level of artifacts and high contrast
- Visibility and positional stability for minimum 2 months after injection
- Visible on CBCT at volume of 10µL and larger
- Injected with no change in current equipment or procedures
- Can be injected using thin needles up to 25G
- Can be injected either percutaneously or using an endoscope assisted injection method (EUS, EBUS etc.)
- Upon injection a sticky and gel-like fiducial marker is formed in vivo
- Very low Z-value and hence low impact on dose perturbation, making it an ideal fiducial marker for proton therapy
- The size of the marker can be adjusted during the injection based on the injection volume, this can be clearly seen during image guided injection
- Numerous markers in one ampoule and can be injected in one procedure
Radiotherapy is the most cost-effective treatment modality for many cancers and approximately 50% of all cancer patients receive radiotherapy as a part of their treatment.
The main challenge in radiotherapy is to administer a sufficiently high dose to the cancer cells with minimal damage to the surrounding healthy tissue. Tumor motion and inadequate patient set-up are two important factors, which constitute this challenge.
Image-guided radiation therapy (IGRT) is a method of radiation therapy that incorporates imaging techniques during each treatment session. IGRT is employed to mitigate errors derived from tumor motion and inadequate patient set-up. The benefits of IGRT includes:
- Accurate delivery of radiation
- Improved definition, localization and monitoring of tumor position, size and shape before and during treatment
- The possibility of higher, targeted radiation dosage to improve tumor control
- Decreased radiation exposure to normal tissue surrounding the tumor
IGRT requires use of frequent imaging and good visibility of tumors and organs at risks. However, soft tissue targets are most often not visible on x-ray images due to a very low tumor to tissue contrast ratio. Hence, soft tissue markers are placed in proximity to the tumor to work as an accurate surrogate.
The availability of radiation therapy equipment with IGRT has been steadily increasing since its introduction more than 15 years ago. Almost all new equipment has IGRT capability.